Galectin Therapeutics Inc. (GALT) Receives Buy Rating from Seaport Global Securities

Galectin Therapeutics Inc. (NASDAQ:GALT)‘s stock had its “buy” rating restated by equities research analysts at Seaport Global Securities in a research report issued on Friday, MarketBeat reports. They presently have a $5.00 target price on the stock. Seaport Global Securities’ price objective indicates a potential upside of 91.57% from the stock’s current price.

Several other research firms also recently weighed in on GALT. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine raised Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Galectin Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.50.

Shares of Galectin Therapeutics (NASDAQ GALT) opened at 2.61 on Friday. The stock has a 50 day moving average price of $1.93 and a 200-day moving average price of $2.32. The stock’s market capitalization is $91.48 million. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same period in the previous year, the company posted ($0.20) EPS. On average, equities research analysts anticipate that Galectin Therapeutics will post ($0.53) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics Inc. (GALT) Receives Buy Rating from Seaport Global Securities” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/08/galectin-therapeutics-inc-galt-coverage-initiated-at-seaport-global-securities.html.

Institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares in the last quarter. KCG Holdings Inc. boosted its holdings in shares of Galectin Therapeutics by 1.9% during the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after purchasing an additional 1,592 shares during the last quarter. Virtu KCG Holdings LLC boosted its holdings in shares of Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after purchasing an additional 21,008 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Galectin Therapeutics by 30.9% during the first quarter. US Bancorp DE now owns 118,921 shares of the company’s stock worth $274,000 after purchasing an additional 28,087 shares during the last quarter. Finally, Advisor Gr

Several other research firms also recently weighed in on GALT. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine raised Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Galectin Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.50.

Shares of Galectin Therapeutics (NASDAQ GALT) opened at 2.61 on Friday. The stock has a 50 day moving average price of $1.93 and a 200-day moving average price of $2.32. The stock’s market capitalization is $91.48 million. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same period in the previous year, the company posted ($0.20) EPS. On average, equities research analysts anticipate that Galectin Therapeutics will post ($0.53) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics Inc. (GALT) Receives Buy Rating from Seaport Global Securities” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/08/galectin-therapeutics-inc-galt-coverage-initiated-at-seaport-global-securities.html.

Institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares in the last quarter. KCG Holdings Inc. boosted its holdings in shares of Galectin Therapeutics by 1.9% during the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after purchasing an additional 1,592 shares during the last quarter. Virtu KCG Holdings LLC boosted its holdings in shares of Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after purchasing an additional 21,008 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Galectin Therapeutics by 30.9% during the first quarter. US Bancorp DE now owns 118,921 shares of the company’s stock worth $274,000 after purchasing an additional 28,087 shares during the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Galectin Therapeutics by 10.4% during the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after purchasing an additional 45,700 shares during the last quarter. 11.18% of the stock is owned by institutional investors.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply